Development of AntiRetroviral Therapy in Africa (DART) study post hoc safety data analysis comparing safety outcomes of study participants with baseline creatinine clearance of 30-49 mL/min vs participants with creatinine clearance of ≥50 mL/min

First published: 18/06/2018
Last updated: 02/04/2024





## Administrative details

#### **EU PAS number**

**EUPAS24473** 

Study ID

48250

**DARWIN EU® study** 

No

**Study countries** 

Uganda
Zimbabwe

#### **Study description**

This report describes the ViiV Healthcare initiated post-hoc analyses for the 96 week safety outcome comparison of study participants with baseline creatinine clearance (CLcr) of 30-49 mL/min vs participants with CLcr of ≥50 mL/min from the completed open-label interventional Development of AntiRetroviral Therapy in Africa trial (DART), a randomized study where 3316 participants received an antiretroviral therapy regimen containing 150 mg twice daily dose of lamivudine, dosed as a fixed dose combination of lamivudine and zidovudine (COMBIVIR) plus a third antiretroviral drug of either tenofovir, abacavir or nevirapine, the original protocol for the completed DART study has been supplied with results from the ViiV Healthcare post hoc analysis.

#### **Study status**

Finalised

## Research institutions and networks

## **Institutions**

## ViiV Healthcare

First published: 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### **Study institution contact**

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor Pharma.CDR@gsk.com

Study contact

Pharma.CDR@gsk.com

### **Primary lead investigator**

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

**Primary lead investigator** 

# Study timelines

## Date when funding contract was signed

Planned: 09/02/2017 Actual: 09/02/2017

#### **Study start date**

Planned: 14/02/2017 Actual: 14/02/2017

#### Date of final study report

Planned: 12/03/2018 Actual: 16/04/2018

## Sources of funding

• Pharmaceutical company and other private sector

## More details on funding

ViiV Healthcare

## Study protocol

viiv-208674-protocol-redact.pdf (1.18 MB)

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

## Study type

# Study type list

### **Study topic:**

Disease /health condition

Human medicinal product

#### Study type:

Not applicable

#### If 'other', further details on the scope of the study

Post-hoc analyses of 96 week safety outcome comparison of study participants with baseline creatinine clearance (CLcr) of 30-49 mL/min vs participants with CLcr of  $\geq$ 50 mL/min from the open-label Development of AntiRetroviral Therapy in Africa trial

#### Main study objective:

To describe the post-hoc analyses for the 96 week safety outcome comparison of study participants with baseline creatinine clearance (CLcr) of 30-49 mL/min vs participants with CLcr of  $\geq$ 50 mL/min from the open-label Development of AntiRetroviral Therapy in Africa trial (DART).

## Study drug and medical condition

## Study drug International non-proprietary name (INN) or common name

LAMIVUDINE

**ZIDOVUDINE** 

**ABACAVIR** 

**NEVIRAPINE** 

**TENOFOVIR** 

#### Medical condition to be studied

HIV infection

# Population studied

#### Short description of the study population

Patients aged 18 years or older with HIV infection in Africa.

#### Inclusion criteria:

- 1. Documentation of HIV-1 infection: antibody positive serology by ELISA test (confirmed by licensed second ELISA or Western Blot).
- 2. Age > 18 years
- 3. Symptomatic WHO stage 2, 3 or 4 HIV disease and CD4 < 200 cells/mm3
- 4. ART naïve (except for ART use during pregnancy for the prevention of mother-to-child HIV transmission).
- 5. Agreement and documented informed consent to be randomised to CMO or LCM and to STI or continuous ART, if eligible.
- 6. Life expectancy of at least 3 months

#### Exclusion criteria:

- 1. Cannot, or unlikely to attend regularly (e.g. usual residence too far from Study Centre)
- 2. Likelihood of poor compliance
- 3. Presence of acute infection (e.g. malaria, acute hepatitis, pneumococcal pneumonia, non-typhoid salmonella septicaemia, cryptococcal meningitis). Patients may be admitted after recovery of an acute infection. Patients with tuberculosis (TB) will not be enrolled while on the intensive phase of antituberculosis therapy, but should be re-evaluated after the intensive phase and a decision made then about starting ART. Patients starting ART whilst on antituberculosis therapy after the intensive phase will not receive NVP, nor will they be randomised into the NORA substudy.
- 4. On chemotherapy for malignancy
- 5. Laboratory abnormalities which are a contra-indication for the patient to start ART (e.g. Haemoglobin <8g/dl, neutrophils <0.50x109/l, AST or ALT >5x the upper limit of normal (ULN), grade 3 renal dysfunction creatinine >360 mol/l

and/or urea >5 x

ULN).

6. Pregnancy or breast-feeding

#### Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

#### **Special population of interest**

Immunocompromised

Other

#### Special population of interest, other

Patients with HIV infection

#### **Estimated number of subjects**

3316

# Study design details

#### **Outcomes**

Safety events, effect of ART initiation on renal function over 96 weeks.

#### Data analysis plan

Descriptive statistics were used to compare safety outcomes over a period of 96 weeks for study participants that entered the study with baseline renal function of CLcr 30-49 mL/min to those with baseline CLcr ≥50 mL/min. The

adverse event rates for common adverse events for participants treated with any antiretroviral drug with baseline CLcr 30-49 mL/min and those with baseline CLcr ≥50 mL/min) were evaluated and the relative risk and 95% confidence intervals were presented. This was not a powered study and no multiple comparisons were adjusted.

### **Documents**

#### Study results

viiv-208674-clinical-study-report-redact.pdf (4.68 MB)

## Data management

## **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

#### Data sources (types)

Other

## Data sources (types), other

Post hoc analysis of specific safety outcomes obtained from the previously completed Medical Research Council Sponsored DART study

## Use of a Common Data Model (CDM)

### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

## **Check completeness**

Unknown

### **Check stability**

Unknown

## **Check logical consistency**

Unknown

## Data characterisation

#### **Data characterisation conducted**

No